CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced the launch of Expression of Hope III, a global program of inspiration and awareness featuring works of art by the community of people affected by lysosomal storage disorders (LSD). This unique program encourages anyone affected by an LSD to create and submit a work of art that expresses their experiences of living with a rare, inherited disease. Through the Expression of Hope program, Genzyme furthers its long-standing history of collaboration with patient advocacy organizations around the world to help raise awareness and build a stronger global network of support for people affected by LSDs.
“Being diagnosed with a lysosomal storage disorder often creates a sense of isolation for patients and families,” said Jamie Ring, Genzyme’s vice president of global patient advocacy and humanitarian programs, adding, “Through Expression of Hope, anyone whose life has been touched by an LSD – including caregivers, family members, and friends – is invited to use the power of art to share their unique story with the world. Our goal is to use works of art to help more people learn about the impact of LSDs and join the effort to support people affected by them.”
The Expression of Hope program will be accepting submissions through December 5, 2014. Submitted artwork that meets program guidelines will be exhibited in the online gallery on the Expression of Hope web site (www.expressionofhope.com). Select works of art will also be featured in art exhibitions and program materials beginning in 2015.
Through Expression of Hope, anyone who has been touched by an LSD can submit an original work of art on paper or canvas, such as a painting, photograph or sketch. Artists of all ages and artistic ability, including family members, friends and healthcare workers, can participate. Once an artist has completed a piece, it should be photographed and digitally submitted to the Expression of Hope website. All submitted works that meet entry criteria will be presented on the Expression of Hope website. When the submission period closes on December 5, 2014, a panel of art experts will then identify submissions to be designated as Featured Art, which will be displayed in global exhibits and materials. LSD patient organizations around the world are invited to participate in Expression of Hope by promoting the program in their communities. To learn more about Expression of Hope or to submit a work of art, visit www.expressionofhope.com.
Lysosomal storage disorders, also known as lipid storage disorders, are a group of inherited metabolic conditions in which fatty materials (lipids) accumulate in various cells and tissues in the body. People with these disorders either do not produce enough of an enzyme required to break down (metabolize) lipids, or they produce enzymes that do not work properly. Over time, the build-up of lipids can lead to cellular and tissue damage, particularly in the brain, peripheral nervous system, liver, spleen, and bone marrow.1 Examples of LSDs include Gaucher disease and Fabry disease.
About Expression of Hope
Expression of Hope is a global program of inspiration and awareness featuring works of art by the lysosomal storage disorder community. In collaboration with LSD patient organizations around the world, Genzyme launched the Expression of Hope program in 2006 to give those impacted by lysosomal storage disorders (LSDs) the opportunity to raise awareness of these rare genetic diseases. More than 100 patients and caregivers expressed their unique stories through their original pieces of artwork. Building on that initial success, Genzyme launched the second Expression of Hope program in 2009, and once again the global community responded with enthusiasm, creativity and insight. The third Expression of Hope program further reinforces the commitment of individuals affected by lysosomal storage disorders to building awareness and expressing their unique stories through art.